Immunogenicity and Safety Study to Evaluate Different Formulations of GSK Biologicals' Influenza Vaccine GSK576389A

PHASE2CompletedINTERVENTIONAL
Enrollment

2,007

Participants

Timeline

Start Date

October 8, 2007

Primary Completion Date

June 10, 2008

Study Completion Date

June 10, 2008

Conditions
Influenza
Interventions
BIOLOGICAL

GlaxoSmithKline Biologicals' influenza vaccine GSK576389A

Single dose, Intramuscular injection, 8 different formulations were tested (one per group)

BIOLOGICAL

Fluarix

Single dose, Intramuscular injection

Trial Locations (30)

10435

GSK Investigational Site, Berlin

12627

GSK Investigational Site, Berlin

13347

GSK Investigational Site, Berlin

13359

GSK Investigational Site, Berlin

22335

GSK Investigational Site, Hamburg

22415

GSK Investigational Site, Hamburg

39112

GSK Investigational Site, Magdeburg

39326

GSK Investigational Site, Wolmirstedt

45359

GSK Investigational Site, Essen

51069

GSK Investigational Site, Cologne

55131

GSK Investigational Site, Mainz

55624

GSK Investigational Site, Rhaunen

68161

GSK Investigational Site, Mannheim

69469

GSK Investigational Site, Weinheim

73635

GSK Investigational Site, Rudersberg

74363

GSK Investigational Site, Güglingen

86150

GSK Investigational Site, Augsburg

01067

GSK Investigational Site, Dresden

01705

GSK Investigational Site, Freital

04103

GSK Investigational Site, Leipzig

3011 EN

GSK Investigational Site, Rotterdam

3015 GE

GSK Investigational Site, Rotterdam

SE-631 88

GSK Investigational Site, Eskilstuna

SE-371 41

GSK Investigational Site, Karlskrona

SE-751 85

GSK Investigational Site, Uppsala

RG2 0TG

GSK Investigational Site, Reading

PR7 7NA

GSK Investigational Site, Buckshaw Village, Chorley

G81 2DR

GSK Investigational Site, Clydebank, Glasgow

B15 2SQ

GSK Investigational Site, Edgbaston, Birmingham

L22 0LG

GSK Investigational Site, Waterloo, Liverpool

Sponsors

Lead Sponsor

All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT00540592 - Immunogenicity and Safety Study to Evaluate Different Formulations of GSK Biologicals' Influenza Vaccine GSK576389A | Biotech Hunter | Biotech Hunter